Synaptonemal Complex Protein 3 Transcript Analysis in Breast Cancer
Abstract
Background: Breast cancer is the most frequent cancer in women. Cancer/Testis antigens are immunogenic proteins ectopically expressed in human neoplasms. Synaptonemal complex protein 3 (SYCP3) belongs to cancer/testis genes family involved in meiotic events and spermatogenesis. The aim of this study was to express analysis of SYCP3 in breast cancer and validate it as a breast cancer biomarker.
Methods: Expression of SYCP3 transcripts in 47 breast tumors, 6 breast cancer cell lines (MCF7, SKBR3, T47D, BT474, MDA-MB-231 and MDA-MB 468), 5 normal breast and 2 testis tissues was studied by Real Time RT-PCR reaction. The reference genes phosphoglucomutase 1 and hypoxanthine guanine phosphoribosyl transferase were used as reactions normalizers. The software tool REST 2009 was applied for statistical analysis of the data. The research was conducted from Apr 2014 to August 2015 in Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Results: All of the studied breast cancer cell lines showed very high levels of SYCP3 overexpression in comparison to normal breast (P=0.001) and even to normal testis (P=0.001), except for MCF7 cell line. Breast tumors showed moderately increasing in transcript changes in comparison to normal breast.
Conclusion: SYCP3 is a known testis-specific gene, but interestingly five out of six studied breast cancer of cell lines showed higher expression levels of SYCP3 in comparison to normal testis and normal breast tissues. SYCP3 has critical role in cell division with known interaction with the tumor suppressor genes, BRCA1 and BRCA2, which are critical genes in breast cancer.
Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. Ca Cancer J Clin, 62(1):10-2.
Saini S, Jagadish N, Gupta A, Bhatnagar A, Suri A (2013 ). A novel cancer testis antigen, A-Kinase anchor protein 4 (AKAP4) is a potential biomarker for breast cancer. PLoS One, 8(2):e57095.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, et al (2007). American Society of Clinical Oncology 2007 Update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 25(33):5287-312.
Pandey A, Kurup A, Shrivastava A, Radhi S, Nguyen DD, Arentz C et al (2012). Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol, 31(5):302-20.
Grizzi F, Mirandola L, Qehajaj D, Cobos E, Figueroa JA, Chiriva-Internati M (2015). Cancer-testis antigens and immunotherapy in the light of cancer complexity. Int Rev Immunol, 34(2):143-53.
Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005). Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer, 5(8):615-25.
Mobasheri MB, Shirkoohi R, Zendehdel K, Jahanzad I, Talebi S, Afsharpad M, Modarressi MH (2015). Transcriptome analysis of the cancer/testis genes, DAZ1, AURKC, and TEX101, in breast tumors and six breast cancer cell lines. Tumour Biol, 36(10):8201-6.
Yazarloo F, Shirkoohi R, Mobasheri MB, Emami A, Modarressi MH (2013). Expression analysis of four testis-specific genes AURKC, OIP5, PIWIL2 and TAF7L in acute myeloid leukemia: a gender-dependent expression pattern. Med Oncol, 30(1):368.
Eisenberg ML, Betts P, Herder D, Lamb DJ, Lipshultz L (2013) .Increased risk of cancer among azoospermic men. Fertil Steril, 100(3):681-5.
Kelly RJ, Giaccone G (2011). Lung cancer vaccines. Cancer J, 17(5):302-8.
Adamah DJ, Gokhale PJ, Eastwood DJ, Rajpert De-Meyts E, Goepel J, Walsh JRet al (2006). Dysfunction of the mitotic:meiotic switch as a potential cause of neoplastic conversion of primordial germ cells. Int J Androl, 29(1):219-27.
Kouznetsova A, Wang H, Bellani M, Camerini-Otero RD, Jessberger R, Höög C (2009). BRCA1-mediated chromatin silencing is limited to oocytes with a small number of asynapsed chromosomes. J Cell Sci, 122(Pt 14):2446-52.
Hosoya N1, Okajima M, Kinomura A, Fujii Y, Hiyama T, Sun J, Tashiro S, Miyagawa K (2011). Synaptonemal complex protein SYCP3 impairs mitotic recombination by interfering with BRCA2. EMBO Rep, 23; 13(1):44-51.
Deborah L Holliday and Valerie Speirs (2011). Choosing the right cell line for breast cancerresearch. Breast Cancer Res, 13(4):215.
Pfaffl MW, Horgan GW, Dempfle L (2002). Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res, 30(9): e36
Charafe-Jauffret, C Ginestier, F Monville1, P Finetti, J Ade, laı de, et al (2006). Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene, 25(15):2273-84.
Whitehurst AW (2014). Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol, 54:251-72.
Ghafouri-Fard S, Shamsi R, Seifi-Alan M, Javaheri M, Tabarestani S (2014). Cancer-testis genes as candidates for immunotherapy in breast cancer. Immunotherapy, 6(2):165-79.
Dianatpour M, Mehdipour P, Nayernia K, Mobasheri MB, Ghafouri-Fard S, Savad S, et al (2012). Expression of Testis-Specific Genes TSGA10, TEX101 and ODF3 in Breast Cancer. Iran Red Crescent Med J, 14(11):722-6.
Mobasheri MB, Shirkoohi R, Modarressi MH (2015). Cancer/Testis OIP5 and TAF7L Genes are Up-Regulated in Breast Cancer. Asian Pac J Cancer Prev, 16(11):4623-8
Mobasheri MB, Jahanzad, Mohagheghi MA, Aarabi M, Farzan S, Modarressi MH (2007). Expression of two testis-specific genes, TSGA10 and SYCP3, in different cancers regarding to their pathological features. Cancer Detect Prev, 31(4):296-302.
Cho H, Noh KH, Chung JY, Takikita M, Chung EJ, Kim BW et al (2014). Synaptonemal complex protein 3 is a prognostic marker in cervical cancer. PLoS One, 6; 9(6):e98712.
Chung JY, Kitano H, Takikita M, Cho H, Noh KH, Kim TW (2013). Synaptonemal complex protein 3 as a novel prognostic marker in early stage non-small cell lung cancer. Hum Pathol, 44(4):472-9.
Litvinov IV, Cordeiro B, Huang Y, Zargham H, Pehr K, Doré MA, et al (2014). Ectopic expression of cancer-testis antigens in cutaneous T-cell lymphoma patients. Clin Cancer Res, 15; 20(14):3799-808
Niemeyer P1, Türeci O, Eberle T, Graf N, Pfreundschuh M, Sahin U (2003). Expression of serologically identified tumor antigens in acute leukemias. Leuk Res, 27(7):655-60.
Bolor H1, Mori T, Nishiyama S, Ito Y, Hosoba E, Inagaki H, et al (2009). Mutations of the SYCP3 gene in women with recurrent pregnancy loss. Am J Hum Genet, 84(1):14-20.
Aarabi M1, Modarressi MH, Soltanghoraee H, Behjati R, Amirjannati N, Akhondi MM (2006). Testicular expression of synaptonemal complex protein 3 (SYCP3) messenger ribonucleic acid in 110 patients with nonobstructive azoospermia. Fertil Steril, 86(2):325-31.
Miryounesi M, Nayernia K, Mobasheri MB, Dianatpour M, Oko R, Savad S, et.al (2014). Evaluation of in vitro spermatogenesis system effectiveness to study genes behavior: monitoring the expression of the testis specific 10 (Tsga10) gene as a model. Arch Iran Med, 17(10):692-7.
Azam R, Ghafouri-Fard S, Tabrizi M, Modarressi MH, Ebrahimzadeh-Vesal R, et al (2014). Lactobacillus acidophilus and Lactobacillus crispatus culture supernatants downregulate expression of cancer-testis genes in the MDA-MB-231 cell line. Asian Pac J Cancer Prev, 15(10):4255-9.
| Files | ||
| Issue | Vol 45 No 12 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| Breast cancer biomarkers Targeted therapy Cancer/testis genes SYCP3 Breast cancer cell lines | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
